Proteo and its subsidiary Proteo Biotech have signed a cooperative research and development agreement with the US Army Medical Research Institute of Infectious Diseases (USAMRIID).
Under the partnership, Proteo will offer USAMRIID with Elafin and related scientific data to plan and conduct preclinical research on the development of new therapeutic strategies to combat life-threatening infectious diseases.
Proteo said that scientists from the USAMRIID are investigating therapies to treat individuals that have become symptomatic after exposure to one of the bacterial bio-threat agents (anthrax, plague, tularaemia, glanders or melioidosis).
One direction their research has taken is to attempt to mitigate or alter the immunological response that in many cases is the ultimate cause of death in these infections. They are interested in investigating if Proteo's Elafin could help as a co-therapy with antibiotics.
Birge Bargmann, CEO of Proteo, said: "We are looking forward to the results of the USAMRIID regarding the use of our lead product, Elafin, in preclinical models."